For instance, treatment with vadastuximab talirine, an anti-CD33 PBD-ADC developed by Seattle Genetics, reached a 70% complete remission rate in AML patients; however, due to the occurrence of several treatment-related fatal events, the clinical development of vadastuximab talirine has been terminated [28]. The gene discussed is CD33; the disease is acute myeloid leukemia.